These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30126000)

  • 1. Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer.
    Deng K; Zhang F; Song W; Zhao W; Rong Z; Cai Y; Xu H; Lu M; Wang W; Li A; Hou Y; Li Z; Li K
    J Cell Biochem; 2018 Nov; 119(10):8564-8573. PubMed ID: 30126000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.
    Zhao H; Guo E; Hu T; Sun Q; Wu J; Lin X; Luo D; Sun C; Wang C; Zhou B; Li N; Xia M; Lu H; Meng L; Xu X; Hu J; Ma D; Chen G; Zhu T
    Oncotarget; 2016 Jul; 7(28):43924-43938. PubMed ID: 27270322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.
    Zhang W; Ota T; Shridhar V; Chien J; Wu B; Kuang R
    PLoS Comput Biol; 2013; 9(3):e1002975. PubMed ID: 23555212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMP-16 as a New Biomarker for Predicting Prognosis and Chemosensitivity of Serous Ovarian Cancer: A Study Based on Bioinformatics Analysis.
    Wang W; Liu Y; Yang Y; Huang X; Hou Y
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):1-8. PubMed ID: 34587431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting time to ovarian carcinoma recurrence using protein markers.
    Yang JY; Yoshihara K; Tanaka K; Hatae M; Masuzaki H; Itamochi H; ; Takano M; Ushijima K; Tanyi JL; Coukos G; Lu Y; Mills GB; Verhaak RG
    J Clin Invest; 2013 Sep; 123(9):3740-50. PubMed ID: 23945238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
    Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
    BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    Le Page C; Rahimi K; Köbel M; Tonin PN; Meunier L; Portelance L; Bernard M; Nelson BH; Bernardini MQ; Bartlett JMS; Bachvarov D; Gotlieb WH; Gilks B; McAlpine JN; Nachtigal MW; Piché A; Watson PH; Vanderhyden B; Huntsman DG; Provencher DM; Mes-Masson AM
    BMC Cancer; 2018 Mar; 18(1):347. PubMed ID: 29587661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
    Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
    Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic risk factors of serous ovarian carcinoma based on mesenchymal stem cell phenotype and guidance for therapeutic efficacy.
    Yang X; Zheng M; Ning Y; Sun J; Yu Y; Zhang S
    J Transl Med; 2023 Jul; 21(1):456. PubMed ID: 37434173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
    Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
    Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
    PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
    Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
    Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.